December 13, 2022 04:30 PM EST

FDA adcomm votes 8-3 against Cytokinetics' potential heart failure drug

Zachary Brennan

Senior Editor

After more than a decade and a half in development, the FDA’s Cardiovascular and Renal Drugs Advisory Committee today voted 8-3 against approval of Cytokinetics’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA adcomm votes 8-3 against Cytokinetics' potential heart failure drug

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers

Eye drop maker to merge with a retinal gene therapy startup from Spark co-founder

UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake

Corrected: Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

FDA ad­comm votes 8-3 against Cy­to­ki­net­ic­s' po­ten­tial heart fail­ure drug

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Mer­ck pays $30M to buy ‘chameleon’ ap­proach to dead­ly brain can­cers

Eye drop mak­er to merge with a reti­nal gene ther­a­py start­up from Spark co-founder

UK’s price watch­dog says Lil­ly’s Alzheimer’s drug is too cost­ly for broad up­take

Cor­rect­ed: Sang­amo to seek ac­cel­er­at­ed ap­proval for Fab­ry gene ther­a­py, claims it won't need con­fir­ma­to­ry study

Am­gen preps to launch Eylea biosim­i­lar years ear­ly af­ter Re­gen­eron los­es ap­peal

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

FDA adcomm votes 8-3 against Cytokinetics' potential heart failure drug

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers

Eye drop maker to merge with a retinal gene therapy startup from Spark co-founder

UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake

Corrected: Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

IDEAYA Biosciences: Targeting unmet market needs with precision oncology